UCB, which recently pulled off a $2.5 billion for an autoimmune drug candidate, says it sees the need for more biopharma production. To fill it, it will build a €300 million ($333 million) facility and staff it with 150 new workers.
The Belgium company says work on the facility will begin soon at its site in Braine l’Alleud, Wallonia, Belgium. The plant is slated to be operational in 2024.
It said the biotechnology plant is needed for the future launch of monoclonal antibody drug therapies in clinical development.
“The shift of our pipeline towards large molecules requires us to ramp up investment in mammalian technical development, as well as our manufacturing capabilities,” Kirsten Lund-Jurgensen, head of supply and technology at UCB, said in a statement.
The announcement comes just two months after UCB struck a deal to acquire Cambridge, Massachusetts biotech Ra Pharmaceuticals. With the takeover, UCB will get a phase 3 rival to Alexion’s Soliris that analysts have pegged to hit blockbuster sales.
The Ra drug candidate is focused on a once-daily, self-administered, subcutaneous C5 inhibitor called zilucoplan which is in phase 3 trials for myasthenia gravis.
MG is a long-term autoimmune neuromuscular condition that causes muscle weakness, particularly affecting the face, but can also extend to the arms legs and neck in more severe cases, known as generalized MG. It can cause difficulties with swallowing, speaking and breathing and in some cases these can become severe—known as a myasthenic crisis—and require hospitalization.
By Eric Palmer
Source: Fierce Pharma
Thermo Fisher Scientific has acquired Novasep’s viral vector manufacturing business in Belgium, Henogen, for about €725m ($874.5m) in cash. Henogen offers biotechnology firms, as well as biopharma customers contract manufacturing services for vaccines and therapies.
Research and development group of Eli Lilly and Company, Loxo Oncology at Lilly, and clinical-stage oncology company Merus have announced a research collaboration and exclusive license agreement to develop T-Cell re-directing bispecific antibodies.
Chinese cancer biotech Adagene has filed to raise up to $125 million in a Nasdaq IPO. The listing will give Adagene the means to run early-phase clinical trials of antibodies against CD137 and CTLA-4.